Positron emission tomography for the staging of Hodgkin's lymphoma: Increasing the body of evidence in favor of the method

Acta Oncologica

Volumn 41, Issue 5, 2002, Pages 430-436

  Menzel, Christian ^a   Döbert, Natascha ^a   Mitrou, Paris ^a   Mose, Stefan ^a   Diehl, Michaela ^a   Berner, Uwe ^a   Grünwald, Frank ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; DIAGNOSIS; MEDICAL APPLICATIONS; TOMOGRAPHY;

OPTIMAL THERAPY;

ONCOLOGY;

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CERVICAL LYMPH NODE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0036405370     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418602320405014     Document Type: Article

References (11)

1. Brandt L, Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in Hodgkin's disease. Acta Oncol 2001; 40: 185-97.
2. Reske SN, Kotzerke J. FDG-PET for clinical use. Eur J Nucl Med 2001; 28: 1707-23.
3. Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81: 20-5.
4. Munker R, Stengel A, Stabler A, et al. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Verification by laparotomy in 100 cases. Cancer 1995; 76: 1460-6.
5. Buchmann I, Moog F, Schirrmeister H, Reske SN. Positron emission tomography and staging of malignant lymphoma. Recent Results Cancer Res 2000; 156: 78-89.
6. Wiedmann E, Baican B, Hertel A, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma 1999; 34: 545-51.
7. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002; 112: 262-8.
8. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91: 3340-6.
9. Moog F, Bangerter M, Kotzerke J, et al. 18F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16: 603-9.
10. Partridge S, Timothy A, O'Doherty MJ, et al. 2-Fluorine-18- fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution. Ann Oncol 2000; 11: 1273-9.
11. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-8.